- Home
- PGNY vs EYPT Comparison
PGNY vs EYPT Comparison
Compare PGNY & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | EYPT |
|---|---|---|
| Founded | 2008 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PGNY | EYPT |
|---|---|---|
| Price | $17.70 | $13.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $27.10 | ★ $31.80 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 05-18-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $1,288,661,000.00 | $7,539,000.00 |
| Revenue This Year | $9.57 | N/A |
| Revenue Next Year | $10.06 | $965.51 |
| P/E Ratio | $26.92 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $16.76 | $3.91 |
| 52 Week High | $28.75 | $19.11 |
Technical Indicators
Market Signals| Indicator | PGNY | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 33.32 | 37.96 |
| Support Level | $16.76 | $11.88 |
| Resistance Level | $22.71 | $14.24 |
| Average True Range (ATR) | 0.97 | 1.12 |
| MACD | 0.05 | -0.45 |
| Stochastic Oscillator | 17.49 | 8.54 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.